• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-3MEF filed by Assembly Biosciences Inc.

    8/7/25 9:42:36 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASMB alert in real time by email
    S-3MEF 1 d54913ds3mef.htm S-3MEF S-3MEF

    As filed with the Securities and Exchange Commission on August 7, 2025

    Registration No. 333-    

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Assembly Biosciences, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   20-8729264

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    Two Tower Place, 7th Floor

    South San Francisco, California 94080

    (833) 509-4583

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Jason A. Okazaki

    Chief Executive Officer and President

    Two Tower Place, 7th Floor

    South San Francisco, California 94080

    (833) 509-4583

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copy to:

    P. Michelle Gasaway, Esq.

    Skadden, Arps, Slate, Meagher & Flom LLP

    2000 Avenue of the Stars

    Suite 200N

    Los Angeles, California 90067

    (213) 687-5000

     

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ (File no. 333-285970)

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☐

     

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    This Registration Statement shall automatically become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(b) of the Securities Act.

     

     
     


    EXPLANATORY NOTE AND INCORPORATION BY REFERENCE

    Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the registrant is filing this Registration Statement on Form S-3 to register the offer and sale of an additional $50,000,000, or the equivalent thereof, of its (a) shares of common stock; (b) shares of preferred stock, which may be issued in one or more series; (c) debt securities, which may be issued in one or more series and which may be senior debt securities or subordinated debt securities; (d) warrants to purchase shares of our common stock, shares of our preferred stock or our debt securities; (e) subscription rights to purchase shares of our common stock, shares of our preferred stock or our debt securities; and (f) units. This Registration Statement relates to the registrant’s Registration Statement on Form S-3 (File No. 333-285970) (the “Prior Registration Statement”), initially filed on March 20, 2025 and declared effective by the Securities and Exchange Commission on April 1, 2025. The required opinion and consents are filed herewith. The additional amount of securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement. Pursuant to Rule 462(b), the contents of the Prior Registration Statement, including the exhibits thereto, are incorporated by reference into this Registration Statement.

     

    1


    EXHIBIT INDEX

     

    Exhibit
    No.

      

    Description of Exhibits

    5.1    Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.*
    23.1    Consent of Independent Registered Public Accounting Firm.*
    23.2    Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1).
    24.1    Power of Attorney.**
    107    Filing Fee Table.*

     

    *

    Filed herewith.

    **

    Previously filed on the signature page of the Registrant’s Registration Statement on Form S-3 (File No. 333-285970), filed with the Securities and Exchange Commission on March 20, 2025, and incorporated by reference herein.

     

    II-1


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California on August 7, 2025.

     

    Assembly Biosciences, Inc.

    By:

     

    /s/ Jason A. Okazaki

     

    Name: Jason A. Okazaki

     

    Title:  Chief Executive Officer and President

    Pursuant to the requirements of the Securities Act of 1933, this registration statement on Form S-3 has been signed by the following persons in the capacities indicated on August 7, 2025.

     

    Signature

          

    Title

    /s/ Jason A. Okazaki.

         Chief Executive Officer, President and Director
    Jason A. Okazaki, A.O., M.D.      (Principal Executive Officer)

    /s/ Jeanette M. Bjorkquist

         VP, Finance
    Jeanette M. Bjorkquist      (Principal Financial Officer and Principal Accounting Officer)

      *

         Chairman of the Board
    William R. Ringo, Jr.     

      *

            Director
    Anthony E. Altig     

      *

         Director
    Tomas Cihlar, Ph.D.     

      *

         Director
    Gina Consylman     

      *

         Director
    Robert D. Cook II     

      *

         Director
    Sir Michael Houghton, Ph.D.     

      *

         Director
    Lisa R. Johnson-Pratt, M.D.     

      *

         Director
    Susan Mahony, Ph.D.     

      *

         Director
    John G. McHutchison, A.O., M.D.     

    *By: /s/ Jason A. Okazaki

        
    Jason A. Okazaki     
    Chief Executive Officer and President     
    Attorney-in-Fact     

     

    II-2

    Get the next $ASMB alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASMB

    DatePrice TargetRatingAnalyst
    8/18/2025$50.00Buy
    H.C. Wainwright
    3/25/2025$31.00Buy
    Guggenheim
    9/20/2024$2.00 → $35.00Hold → Buy
    Jefferies
    9/13/2021$3.50Neutral
    HC Wainwright & Co.
    9/2/2021Outperform → Market Perform
    William Blair
    More analyst ratings

    $ASMB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Assembly Biosciences with a new price target

    H.C. Wainwright resumed coverage of Assembly Biosciences with a rating of Buy and set a new price target of $50.00

    8/18/25 8:55:27 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Assembly Biosciences with a new price target

    Guggenheim initiated coverage of Assembly Biosciences with a rating of Buy and set a new price target of $31.00

    3/25/25 8:26:24 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences upgraded by Jefferies with a new price target

    Jefferies upgraded Assembly Biosciences from Hold to Buy and set a new price target of $35.00 from $2.00 previously

    9/20/24 7:32:14 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PFO and PAO Bjorkquist Jeanette M was granted 300 shares, increasing direct ownership by 6% to 5,097 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/17/25 4:05:04 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Houghton Michael

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/9/25 4:05:21 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Mahony Susan

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    6/9/25 4:05:19 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Assembly Biosciences Announces Pricing of $175 Million in Equity Financings

    SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. ("Assembly Bio") (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the "offering") of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded wa

    8/8/25 8:05:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes

    – 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to placebo over same period – – Favorable safety and tolerability profile observed in the first two cohorts evaluating weekly oral doses of ABI-5366 – SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral di

    8/8/25 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

    – Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-6250, supporting target daily oral dosing profile and dose-dependent elevations in biomarker of target engagement – – Further pharmacological assessment to be conducted in parallel with Phase 2 preparation – SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced interim data from several cohorts from the ongoing Phase 1a clinical trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis

    8/6/25 4:05:00 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Assembly Biosciences Inc.

    SCHEDULE 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    8/18/25 5:52:05 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Assembly Biosciences Inc.

    SCHEDULE 13G/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    8/18/25 4:18:39 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Assembly Biosciences Inc.

    SCHEDULE 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    8/15/25 6:56:48 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Houghton Michael bought $49,998 worth of shares (3,202 units at $15.61) (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/31/24 4:24:14 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gilead Sciences, Inc. bought $20,098,464 worth of shares (940,499 units at $21.37), increasing direct ownership by 74% to 2,209,471 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    12/23/24 8:26:39 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Schornstein Alexander bought $371,994 worth of shares (25,000 units at $14.88), increasing direct ownership by 4% to 728,113 units (SEC Form 4)

    4 - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Issuer)

    11/26/24 9:15:02 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASMB
    Leadership Updates

    Live Leadership Updates

    View All

    Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

    -- Dr. Gaggar is an experienced industry executive with substantial infectious disease expertise and proven record of successfully leading early- and clinical-stage antiviral programs -- SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that Anuj Gaggar, MD, PhD, has joined the company as chief medical officer. Dr. Gaggar is an infectious disease specialist and seasoned executive whose experience has focused on the development of new therapies in viral diseases including chronic hepatitis B virus (HBV), hepatitis C vi

    11/8/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes

    −ABI-5366 Demonstrates Favorable Profile for a Long-Acting Therapeutic in Preclinical Studies −IND-Enabling Studies Initiating for 5366, Supporting Anticipated IND/CTA Filing in 1H2024 SOUTH SAN FRANCISCO, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced the selection of development candidate ABI-5366 (5366) to progress to IND-enabling studies for its long-acting herpes simplex virus type 2 (HSV-2) helicase inhibitor program. 5366 is the first development candidate from Assembly Bio's discovery pipeline nominated for adv

    2/15/23 8:00:00 AM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

    Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB). Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB. Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D. "I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board," said Dr. Walter Strapps, co-founder and CEO of Carver. "Along with Dr. Myhrvold, these scientific leaders will help us shape our pipeline and advance our programs into the clinic." Uri Lopatin, M.D. Dr. Lopatin is a serial biotech entrepreneur who founde

    1/17/23 7:00:00 AM ET
    $ASMB
    $PRDS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medicinal Chemicals and Botanical Products

    $ASMB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Assembly Biosciences Inc.

    SC 13G - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    11/14/24 3:22:29 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/24/24 4:28:09 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Assembly Biosciences Inc.

    SC 13D/A - ASSEMBLY BIOSCIENCES, INC. (0001426800) (Subject)

    6/20/24 8:35:37 PM ET
    $ASMB
    Biotechnology: Pharmaceutical Preparations
    Health Care